North Lincolnshire and Goole Hospitals NHS Foundation Trust, Grimsby, UK.
J Orthop Traumatol. 2013 Sep;14(3):171-7. doi: 10.1007/s10195-013-0235-1. Epub 2013 Apr 6.
An increasing number of elderly patients are managed with long-term antiplatelet therapy. Such patients often present with hip fracture requiring surgical intervention and may be at increased risk of perioperative bleeding and complications. The aim of this study was to ascertain whether it is necessary to stop clopidogrel preoperatively to avoid postoperative complications following hip hemiarthroplasty surgery in patients with intracapsular hip fracture.
A retrospective review of 102 patients with intracapsular hip fracture with either perioperative clopidogrel therapy [clopidogrel group (CG)] or no previous clopidogrel exposure [no clopidogrel group (NCG)] who underwent hip hemiarthroplasty surgery was undertaken. Statistical comparison on pre- and postoperative haemoglobin, American Society of Anesthesiologists (ASA) grade, comorbidities, operative time, transfusion requirements, hospital length of stay (LOS), wound infection, haematoma and reoperation rate between the two groups was undertaken. Regression analysis was undertaken to ascertain the risk ratios (RR) of complications and transfusion associated with clopidogrel.
There was no difference with respect to ASA grade, comorbidities (except cardiac comorbidities), pre- and postoperative haemoglobin levels, operation time, age or gender between the two groups. Four and two patients, respectively, required transfusion postoperatively in the CG and NCG (p = 0.37). There was no difference with respect to LOS, wound infection, haematoma or reoperation rate between the two groups postoperatively. The covariate-adjusted RR for complications and transfusion while being on clopidogrel were 0.43 [95% confidence interval (CI) 0.07-2.60] and 3.96 (95% CI 0.40-39.68), respectively.
Continuing clopidogrel therapy throughout the perioperative period in patients with intracapsular hip fracture is not associated with an increased risk of complications following hip hemiarthroplasty surgery.
越来越多的老年患者需要长期接受抗血小板治疗。这些患者常因髋部骨折需要接受手术治疗,并且可能有更高的围手术期出血和并发症风险。本研究旨在确定对于囊内髋部骨折患者,在接受髋关节半髋关节置换术时是否需要术前停用氯吡格雷以避免术后并发症。
回顾性分析了 102 例接受髋关节半髋关节置换术的囊内髋部骨折患者,其中围手术期使用氯吡格雷治疗(氯吡格雷组 [CG])或无先前氯吡格雷暴露史(无氯吡格雷组 [NCG])。比较两组患者的血红蛋白、美国麻醉医师协会(ASA)分级、合并症、手术时间、输血需求、住院时间(LOS)、伤口感染、血肿和再手术率。采用回归分析确定与氯吡格雷相关的并发症和输血的风险比(RR)。
两组患者的 ASA 分级、合并症(除心脏合并症外)、术前和术后血红蛋白水平、手术时间、年龄和性别无差异。CG 组和 NCG 组分别有 4 例和 2 例患者术后需要输血(p = 0.37)。两组患者术后 LOS、伤口感染、血肿或再手术率无差异。调整协变量后,氯吡格雷组发生并发症和输血的 RR 分别为 0.43(95%CI 0.07-2.60)和 3.96(95%CI 0.40-39.68)。
对于囊内髋部骨折患者,在围手术期继续使用氯吡格雷治疗不会增加髋关节半髋关节置换术后并发症的风险。